Ractigen Therapeutics
China - Nantong
BiotechnologyFocus: Small activating RNA
Ractigen Therapeutics is a life sciences company focused on Small activating RNA.
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT06556394A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
Phase 1Phase 1
Clinical Trials (1)
NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy
Phase 1Phase 1
Clinical Trials (1)
NCT06351904A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Phase 1RAG-17
Gene MutationClinical Trials (1)
NCT05903690Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
Phase 1Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2017
Portfolio: 4 clinical trials